Clinical study of Dengzhan Shengmai Capsules combined with ivabradine in treatment of chronic heart failure
Objective To explore the clinical efficacy of Dengzhan Shengmai Capsules combined with ivabradine in treatment of chronic heart failure.Methods A total of 200 patients with chronic heart failure admitted to Shanghai Pudong Hospital from June 2020 to June 2022 were selected and divided into control group and treatment group according to odd-even numbers,with 100 patients in each group.Patients in the control group were po administered with Ivabradine Hydrochloride Tablets at meal time,5 mg/time,twice daily.Patients in the treatment group were po administered with Dengzhan Shengmai Capsules on the basis of the control group,2 capsules/time,3 times daily.Both groups were treated for 2 months.After treatment,clinical efficacy,clinical symptom score,NYHA cardiac function grade,myocardial remodeling indexer,serological and serum inflammation index,Minnesota Quality of Life(LiHFe)score and 6-minute walking test(6MWT)were observed in two groups.Results After treatment,the total effective rate of the treatment group was 94.00%,which was significantly higher than that of the control group 85.00% (P<0.05).After treatment,the clinical symptom score,NYHA grade score,left ventricular end-diastolic diameter(LVEDd)and left ventricular end-systolic diameter(LVESd)levels in treatment group were significantly lower than before treatment(P<0.05).After treatment,the clinical symptom score,cardiac function and myocardial remodeling indexes in the treatment group were significantly lower than those in the control group(P<0.05).After treatment,whole blood high shear viscosity(HBV),whole blood low shear viscosity(LBV),plasma viscosity(PV)and fibrinogen(FIB)were significantly decreased in both groups,while oxygenation index(pO2/FiO2)was significantly increased(P<0.05).After treatment,HBV,LBV,PV and FIB in the treatment group were lower than those in the control group,and pO2/FiO2 was significantly higher than that in the control group(P<0.05).After treatment,the levels of high-sensitivity troponin(hs-cTnT),amino-terminal procardiac natriuretic peptide(NT-proBNP)and serum brain natriuretic peptide(BNP)in 2 groups were significantly decreased compared with those before treatment(P<0.05).After treatment,serological indexes in the treatment group were lower than those in the control group(P<0.05).After treatment,hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)were significantly decreased in 2 groups compared with before treatment(P<0.05).After treatment,the level of inflammation index in the treatment group was significantly lower than that in the control group(P<0.05).After treatment,LiHFe score was significantly decreased in both groups,while 6MWT was significantly increased(P<0.05).After treatment,LiHFe score in the treatment group was lower than that in the control group,and 6MWT score was higher than that in the control group(P<0.05).Conclusion Dengzhan Shengmai Capsules combined with ivabradine has a good effect in treatment of chronic heart failure,can not only promote myocardial remodeling,improve myocardial energy metabolism,improve hemodynamics,rheology and serological indexes,but also reduce the level of inflammation in the body,reduce the LiHFe score and increase the distance of 6MWT.
NETL
NSTL
万方数据
